by ankyratx1dev | Nov 17, 2025
Ankyra Therapeutics Announces First Patient Dosed in Phase 1b Trial Evaluating First-in-Class Anchored Immunotherapy in Combination with Immune Checkpoint Blockade in Patients with Lung Cancer Phase 1b LANTERN clinical study is assessing tolododekin alfa, anchored...
by ankyratx1dev | Nov 4, 2025
Ankyra announces publication of Phase 1 clinical data, and will present at the Society for Immunotherapy of Cancer (SITC) annual meeting Initial Phase 1 data, recently published in Nature Communications, demonstrated clinical activity with no dose limiting toxicity in...
by ankyratx1dev | Apr 28, 2025
Ankyra Therapeutics announced preliminary clinical data today from Part 1 of their Phase 1 ANCHOR study evaluating an anchored IL-12 drug conjugate, tolododekin alfa, as monotherapy in patients with solid tumors Ankyra also announced the first patient has been dosed...
by ankyratx1dev | Jan 10, 2025
JANUARY 10, 2025 (CAMBRIDGE, MA) – Ankyra Therapeutics, a clinical-stage biotech company developing anchored drug conjugates for the treatment of cancer, today announced an expanded collaboration with Johnson & Johnson* to advance the clinical development of...
by Anand Patadiya | Nov 5, 2024
Safety and tolerability to be determined at up to 5 study sites in the United States and Canada November 5, 2024 (Cambridge, MA) – Ankyra Therapeutics, a clinical stage biotechnology company pioneering anchored therapy to treat cancer, today announced the first...
